Reducing cardiorenal risk through combination therapy with a direct renin inhibitor (Q26851307)

Mohamad Rashid

series ordinal

2

1 reference

Richard F. Wright

series ordinal

3

1 reference

language of work or name

1 reference

November 2011

1 reference

Journal of Clinical Hypertension

published in

1 reference

volume

13

1 reference

issue

11

1 reference

page(s)

848-55

1 reference

Renin-angiotensin system revisited

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

Recent changes in the landscape of combination RAS blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

Aliskiren: an oral direct renin inhibitor for the treatment of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

Novel aspects of the renin-angiotensin-aldosterone-system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

Therapeutic inhibition of the renin angiotensin aldosterone system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

Supramaximal dose of candesartan in proteinuric renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

Managing cardiovascular and renal risk: the potential of direct renin inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

Monitoring and managing urinary albumin excretion: practical advice for primary care clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

7 January 2021

Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

7 January 2021

Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

7 January 2021

Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

7 January 2021

Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

7 January 2021

Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00536.X

7 January 2021

10.1111/J.1751-7176.2011.00536.X

Identifiers

DOI

0 references

Fatcat ID

release_3mne3fpqyjanregim6eocgpcve

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3mne3fpqyjanregim6eocgpcve

24 November 2022

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/3mne3fpqyjanregim6eocgpcve

24 November 2022

mapped directly with Wikidata item

PubMed publication ID

22051431

1 reference